Sign In
Buy SPHDF
$23.25
+0 (+0%)
At Close: Jun 02, 2026
Santhera Pharmaceuticals Holding AG (SPHDF) Q4 2025 Earnings Call Transcript
10:53am, Monday, 04'th May 2026
Santhera Pharmaceuticals Holding AG (SPHDF) Q4 2025 Earnings Call Transcript
eBay heads into Q1 earnings with momentum, but macro clouds loom
12:10pm, Tuesday, 28'th Apr 2026
With eBay Inc (NASDAQ:EBAY, XETRA:EBA) set to report its first-quarter 2026 results on April 29, UBS has bumped its price target on the stock to $110 from...
Santhera reconfirms cash flow breakeven target as AGAMREE revenues near-double
02:31am, Tuesday, 28'th Apr 2026
The Swiss rare disease specialist expects to reach breakeven in the third quarter of 2026 without raising additional funds. Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss specialt
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
01:00am, Tuesday, 28'th Apr 2026
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 28, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT.
Santhera wins backing to extend DMD drug AGAMREE to toddlers as young as two
07:45am, Monday, 27'th Apr 2026
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare disease specialist, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for H
Santhera Pharmaceuticals (OTCMKTS:SPHDF) Trading Up 35.4% – What’s Next?
02:18am, Wednesday, 18'th Feb 2026
Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF - Get Free Report)'s stock price was up 35.4% during mid-day trading on Tuesday. The company traded as high as $22.04 and last traded at $22.04. Appr
Santhera Pharmaceuticals: Delivers life-changing treatment to little fanfare. Soon the numbers will support its progress
08:30am, Friday, 13'th Feb 2026
November 3, 2025, should have registered as a turning point for Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0). Yet, the date passed with little market fanfare, even though it marked the rel
BlackRock shares jump on Q4 earnings, record $14T assets under management
06:21am, Thursday, 15'th Jan 2026
BlackRock Inc (NYSE:BLK) reported fourth quarter 2025 earnings that exceeded Wall Street expectations and ended the year with a record $14 trillion in...
Santhera lands key approval for DMD treatment in Switzerland
04:35am, Thursday, 15'th Jan 2026
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) told investors it has received approval from Swissmedic for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy in patient
Santhera lands key approval for DMD treatment in Switzerland
03:22am, Thursday, 15'th Jan 2026
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) told investors it has received approval from Swissmedic for AGAMREE® (vamorolone) for the treatment...
Aritzia shares rise as Q3 earnings top expectations
06:05am, Friday, 09'th Jan 2026
Aritzia Inc (TSX:ATZ) shares moved higher as it reported fiscal third quarter earnings that topped analyst expectations, driven by growth in both its retail...
Santhera shares jump after $205 million Asia-Pacific licensing deal
05:33am, Thursday, 08'th Jan 2026
Shares in Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) rose 7.4% to CHF 13.14 after the group struck a licensing deal worth up to $205 million plus royalties for its Duchenne muscular dystrophy drug
Santhera shares jump after $205 million Asia-Pacific licensing deal
05:30am, Thursday, 08'th Jan 2026
Shares in Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) rose 7.4% to CHF 13.14 after the group struck a licensing deal worth up to $205 million plus...
Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug
05:08am, Thursday, 08'th Jan 2026
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) has signed a licensing deal worth up to $205 million plus royalties for its Duchenne muscular dystrophy treatment AGAMREE, handing rights in key Asia-Pac
Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug
03:02am, Thursday, 08'th Jan 2026
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) has signed a licensing deal worth up to $205 million plus royalties for its Duchenne muscular dystrophy...
